<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60554">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02121535</url>
  </required_header>
  <id_info>
    <org_study_id>1348.3</org_study_id>
    <nct_id>NCT02121535</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use</brief_title>
  <official_title>Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Hydrochlorothiazide 12.5 mg Tablet in Healthy Male Subjects : an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be performed as an open-label, randomised, single-dose, two-sequence,
      four-period replicated crossover design. A total of 72 Japanese healthy male subjects will
      be randomised to 2 groups. The subjects are administrated either T80/A5/H12.5 mg FDC tablet
      once or T80/A5 mg FDC tablet and hydrochlorothiazide (HCTZ) 12.5 mg tablet once in each
      period. The length of admission will be 7 days in each period.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum measured concentration (Cmax) of the analyte in plasma</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC 0-tz) of the analyte in plasma over the time interval from 0 to the last quantifiable plasma concentration</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC 0-infinity) of the analyte in plasma over the time interval from 0 extrapolated to infinity</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>T80/A5/H12.5 mg FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T80/A5 mg FDC+H12.5 mg mono</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T80/A5 mg FDC tablet</intervention_name>
    <arm_group_label>T80/A5/H12.5 mg FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T80/A5 mg FDC tablet</intervention_name>
    <description>A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet</description>
    <arm_group_label>T80/A5 mg FDC+H12.5 mg mono</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H12.5 mg tablet</intervention_name>
    <arm_group_label>T80/A5/H12.5 mg FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T80/A5/H12.5 ng FDC tablet</intervention_name>
    <description>A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet</description>
    <arm_group_label>T80/A5 mg FDC+H12.5 mg mono</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H12.5 mf tablet</intervention_name>
    <description>A  HCTZ 12.5 mg tablet</description>
    <arm_group_label>T80/A5 mg FDC+H12.5 mg mono</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T80/A5/H12.5 mg FDC tablet</intervention_name>
    <arm_group_label>T80/A5/H12.5 mg FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy male subjects age =20 and =35 years; body weight: =50 kg and =80 kg; body
             mass index: =18.0 and =25.0 kg/m2

          -  Without any clinically significant findings and complications on the basis of a
             complete medical history, including the physical examination, vital signs (blood
             pressure (BP), pulse rate (PR), body temperature), 12-lead electrocardiograms (ECGs),
             clinical laboratory tests

          -  Signed and dated written informed consent prior to admission to the trial in
             accordance with the Good Clinical Practice (GCP) and the local legislation.

        Exclusion criteria:

        - Any finding of the medical examination (including BP, PR and ECGs) deviating from normal
        and of clinical relevance.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1348.3.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Benzoates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
